- Home
- RENB vs OVID Comparison
RENB vs OVID Comparison
Compare RENB & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- OVID
- Stock Information
- Founded
- RENB 2011
- OVID 2014
- Country
- RENB United States
- OVID United States
- Employees
- RENB N/A
- OVID N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- OVID Health Care
- Exchange
- RENB Nasdaq
- OVID Nasdaq
- Market Cap
- RENB 62.0M
- OVID 20.6M
- IPO Year
- RENB N/A
- OVID 2017
- Fundamental
- Price
- RENB $0.33
- OVID $0.56
- Analyst Decision
- RENB
- OVID Strong Buy
- Analyst Count
- RENB 0
- OVID 4
- Target Price
- RENB N/A
- OVID $3.13
- AVG Volume (30 Days)
- RENB 1.8M
- OVID 2.8M
- Earning Date
- RENB 05-15-2025
- OVID 08-12-2025
- Dividend Yield
- RENB N/A
- OVID N/A
- EPS Growth
- RENB N/A
- OVID N/A
- EPS
- RENB N/A
- OVID N/A
- Revenue
- RENB N/A
- OVID $548,000.00
- Revenue This Year
- RENB N/A
- OVID N/A
- Revenue Next Year
- RENB N/A
- OVID $5.32
- P/E Ratio
- RENB N/A
- OVID N/A
- Revenue Growth
- RENB N/A
- OVID 15.61
- 52 Week Low
- RENB $0.26
- OVID $0.24
- 52 Week High
- RENB $2.10
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- RENB 54.77
- OVID 72.15
- Support Level
- RENB $0.26
- OVID $0.30
- Resistance Level
- RENB $0.36
- OVID $0.61
- Average True Range (ATR)
- RENB 0.03
- OVID 0.05
- MACD
- RENB 0.00
- OVID 0.01
- Stochastic Oscillator
- RENB 77.50
- OVID 67.58
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.